119-HR-3491 Journalist Public Summary
119 · HR 3491 DeOndra Dixon INCLUDE Project Act of 2025
H.R. 3491 would formally authorize and expand NIH’s INCLUDE Project to boost research, clinical trials, and training focused on Down syndrome and related health conditions; it has bipartisan backing and advanced from committee 46–0, with House floor action up next.
Public Summary: 119-HR-3491 — DeOndra Dixon INCLUDE Project Act of 2025
Headline Summary: H.R. 3491 formally authorizes a long-term NIH program to accelerate research, clinical trials, and training centered on Down syndrome and co-occurring conditions, with oversight and regular reports to Congress.
What It Does: The bill directs the National Institutes of Health (NIH) to run the INCLUDE Project (“INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE”). It emphasizes high-impact research on how trisomy 21 affects health; expands inclusive and dedicated clinical trials; studies co-occurring conditions (like Alzheimer’s disease and autoimmune disorders); develops biomarkers and new interventions; and supports training and quality‑of‑life research. It also requires NIH to coordinate work across its institutes to avoid duplication, consult with patient advocates, and submit biennial reports to Congress detailing activities and real‑world evidence produced.
- Who’s For It: Bipartisan House sponsors, including Rep. Diana DeGette (D-CO), Rep. Richard Hudson (R-NC), Rep. Rosa DeLauro (D-CT), Rep. Tom Cole (R-OK), Del. Eleanor Holmes Norton (D-DC), and Rep. Pete Stauber (R-MN). They argue the bill will speed discovery, include people with Down syndrome in more trials, and translate findings into better care and everyday supports.
- Broader Support Signals: The Energy and Commerce Committee advanced the bill by a 46–0 vote on May 21, 2026—an indicator of cross‑party support.
- Who’s Against It: No committee members voted no at the May 21, 2026 markup, and the provided record lists no named opponents.
- Potential Concerns Noted in the Text: The bill itself addresses common worries about overlap and efficiency by requiring NIH-wide coordination and prioritizing non‑duplicative research.
What’s Next: After being ordered reported by the House Energy and Commerce Committee on May 21, 2026 (46–0), the measure awaits a committee report and scheduling for House floor consideration. If it passes the House, it would move to the Senate for review and votes.
Discussion